Home/Filings/4/0001144204-13-056563
4//SEC Filing

INTERCEPT PHARMACEUTICALS INC 4

Accession 0001144204-13-056563

CIK 0001270073operating

Filed

Oct 22, 8:00 PM ET

Accepted

Oct 23, 9:31 PM ET

Size

6.0 KB

Accession

0001144204-13-056563

Insider Transaction Report

Form 4
Period: 2013-10-21
Transactions
  • Sale

    Common Stock

    2013-10-21$62.50/sh124,912$7,807,0005,938,890 total(indirect: See Footnote)
Holdings
  • Common Stock

    3,111
Footnotes (2)
  • [F1]These shares are held by Genextra S.p.A. Dr. Tallarigo is the chief executive officer of Genextra S.p.A. and, in such capacity, Dr. Tallarigo exercises voting control over the shares of common stock owned by Genextra S.p.A. and investment control over such shares as authorized by the board of directors of Genextra S.p.A. Dr. Tallarigo disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.
  • [F2]Represents shares of common stock sold under a registration statement on Form S-1 (File No. 333-191501) by Genextra S.p.A. to the underwriter on October 21, 2013 pursuant to the underwriter's partial exercise of its over-allotment option.

Issuer

INTERCEPT PHARMACEUTICALS INC

CIK 0001270073

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001270073

Filing Metadata

Form type
4
Filed
Oct 22, 8:00 PM ET
Accepted
Oct 23, 9:31 PM ET
Size
6.0 KB